ASCO 2020：11项中国研究入围口头报告，17项Poster报告

所致全球新冠疫情不良影响，预定于5翌年29日~6翌年2日在芝加哥举行的American外科学会（ASCO）高峰会今年将首次以线上表达方式举办，这是现在最大规模的线上嘉年华。今天，代表大会的内容可解答发布，共有103个sessions，里面国共有有11项分析荣膺口头报告，17项荣膺Poster

Pyrotinib or lapatinib plus capecitabine for HER2+ metastatic breast cancer (PHOEBE): A randomized phase III trial.Session: Breast Cancer—MetastaticAuthor(s): Binghe Xu, Min Yan, Fei Ma, Xi-Chun Hu, Ji Feng Feng, Quchang Ouyang, Zhongsheng Tong, Huiping Li, Qingyuan Zhang, Tao Sun, Xian Wang, Yongmei Yin, Ying Cheng, Wei Li, Xiaoyu Zhu, Chunxia Chen, Jianjun ZouAbstract: 1003

吡咯替尼或帕尔马替尼加卡培他滨用以HER2+转移持续性乳腺乳癌（PHOEBE）：一项III期随机试验。

首站：转移持续性乳腺乳癌

创作者：里面国医学科学院病房徐兵河博士、马飞博士，复旦大学另设病房胡夕春博士等

内容可号：1003

Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001).

Session: Breast Cancer—Local/Regional/Adjuvant

Author(s): XI Wang, Shu-Sen Wang, Heng Huang, Li Cai, Rou-Jun Peng, Li Zhao, Ying Lin, Jian Zeng, Le-Hong Zhang, Yong-Li Ke, Xian-Ming Wang, Xin-Mei Liu, Qian-Jun Chen, An-Qin Zhang, Dan-Mei Pang, Fei Xu, Jia J. Huang, Yanxia Shi, Jun Tang, Zhongyu Yuan

Abstract: 507

可手术三阴持续性乳腺乳癌准则放射治疗后卡培他滨维系旋律化疗的III期试验（SYSUCC-001）。

首站：乳腺乳癌—大面积/区域/特别设计放射治疗

创作者：里面山大学防治外围王树森博士等

内容可号：507

Utilizing phenotypic characteristics of metastatic brain tumors to predict the probability of circulating tumor DNA detection from cerebrospinal fluid.Session: New Tools to Combat Old FoesAuthor(s): Meichen Li, Delan Li, Xue Hou, Xiangheng Zhang, Na Wang, Jianzhong Liang, Jing Chen, Kaicheng Wang, Fufeng Wang, Yedan Chen, Xian Zhang, Hua Bao, Xue Wu, Xiaonan Wang, Yang Shao, Likun ChenAbstract: 2507

利用转移持续性脑的遗传特征来预测脑脊液里面循环DNA扫描的不确定持续性: 新工具对抗据说对手

首站：新工具解决据说问题

创作者：杨美芹 杨菲尔德等

内容可号: 2507

Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase II/III trial.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Feng Bi, Shukui Qin, Shanzhi Gu, Yuxian Bai, Zhendong Chen, Zishu Wang, Jieer Ying, Yinying Lu, Zhiqiang Meng, Hongming Pan, Ping Yang, Helong Zhang, Xi Chen, Aibing Xu, Xiufeng Liu, Qiu Meng, Liqing Wu, Feng Chen

Abstract: 4506

塔纳非尼对比索拉非尼作为中后期肝细胞会乳癌的预备队放射治疗：一项免费页面、随机、多外围II/III期试验。

首站：肺肠道乳癌—肺食管、坏死和实乃

创作者：四川大学华西病房毕锋博士、里面国当权者解放军朝阳病房秦叔逵博士等

内容可号：4506

Apatinib as second-line therapy in Chinese patients with advanced hepatocellular carcinoma: A randomized, placebo-controlled, double-blind, phase III study.

Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Author(s): Qiu Li, Shukui Qin, Shanzhi Gu, Xiaoming Chen, Lizhu Lin, Zishu Wang, Aibing Xu, Xi Chen, Cuncai Zhou, Zhenggang Ren, Lin Yang, Li Xu, Yuxian Bai, Lei Chen, Jun Li, Hongming Pan, Bangwei Cao, Weijia Fang, Ping Yan, Chunlei Jin

Abstract: 4507

里面国中后期肝乳癌病变阿帕替尼二线放射治疗：一项随机、安慰剂对照、双盲III期分析

首站：肺肠道乳癌—肺食管、坏死和实乃

创作者：里面国当权者解放军朝阳病房秦叔逵博士、四川大学华西病房杨秋博士等

内容可号：4507

A randomized phase III trial of secondary cytoreductive surgery in later recurrent ovarian cancer: SOC1/SGOG-OV2.

Session: Gynecologic Cancer

Author(s): Rongyu Zang, Jianqing Zhu, Tingyan Shi, Jihong Liu, Dongsheng Tu, Sheng Yin, Rong Jiang, Ping Zhang, Huixun Jia, Yuting Luan, Yuqin Zhang, Xiaojun Chen, Xiao Huang, Wenjuan Tian, Wen Gao, Yanling Feng, Huijuan Yang, Xi Cheng, Yulang Cai

Abstract: 6001

中后期罹患持续性卵巢乳癌二次细胞会减灭术的一项随机III期试验：SOC1 / SGOG-OV2。

时事：医学乳白血病

创作者：复旦大学另设里面山病房臧荣余博士等

内容可：6001

Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage IB1-IIA2 cervical cancer (STARS Study): A randomized, controlled, open-label, phase III trial.

Session: Gynecologic Cancer

Author(s): He Huang, Yanling Feng, Ting Wan, Yanna Zhang, Xinping Cao, Yongwen Huang, Ying Xiong, Xin Huang, Min Zheng, Yanfang Li, Jundong Li, Guandi Chen, Hu Li, Yile Chen, Liguo Ma, Hongying Yang, Li Li, Shuzhong Yao, Qing Liu, Jihong Liu

Abstract: 6007

IB1-IIA2期宫颈乳癌根治持续性睾丸手术后特别设计放射治疗里面的序贯放化疗对比除此以外放疗或同步放化疗（STARS分析）：一项随机、对照、免费页面的III期试验。

代表大会：医学乳白血病

创作者：里面山大学防治外围黄鹤博士、刘继红博士等

内容可号：6007

CTONG1104: Adjuvant gefitinib versus chemotherapy for resected N1-N2 NSCLC with EGFR mutation—Final overall survival ysis of the randomized phase III trial 1 ysis of the randomized phase III trial.

Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Author(s): Yi-Long Wu, Wenzhao Zhong, Qun Wang, Weimin Mao, Song-Tao Xu, Lin Wu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, Xiao-Fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, Si-yang Liu, Qing Zhou

Abstract: 9005

CTONG1104：特别设计吉非替尼对比化疗用以可切除的EGFR基因突变的N1-N2期NSCLC-随机III期外科试验的事与愿违总体猎食统计分析。

时事：肺乳癌—非小细胞会大面积-区域/小细胞会/其他胸部

创作者：东莞当权者病房吴一龙博士等

内容可号：9005

First-line tyrosine kinase inhibitor with or without aggressive upfront local radiation therapy in patients with EGFRm oligometastatic non-small cell lung cancer: Interim results of a randomized phase III, open-label clinical trial (SINDAS) (NCT02893332).

Session: Lung Cancer—Non-Small Cell Metastatic

Author(s): Xiaoshan Wang, Ming Zeng

Abstract: 9508

EGFR基因突变寡转移非小细胞会肺乳癌病变预备队乙酰丝氨酸抑制剂倡议或不倡议积极支部队大面积放疗：III期免费页面外科随机试验（SINDAS）的里面期结果（NCT02893332）。

时事：肺乳癌-非小细胞会转移

创作者：四川省当权者病房曾铭博士等

内容可：9508

Overall survival and biomarker ysis of a phase Ib combination study of toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) with axitinib in patients with metastatic mucosal melanoma.

Session: Melanoma/Skin Cancers

Author(s): Xinan Sheng, Xieqiao Yan, Zhihong Chi, Lu Si, Chuanliang Cui, Bixia Tang, Siming Li, Lili Mao, BIN LIAN, Xuan Wang, Xue Bai, Li Zhou, Yan Kong, Jie Dai, Keith Flaherty, Jun Guo

Abstract: 10007

Toripalimab，一种针对程序持续性幸存者-1（PD-1）的人源化IgG4单克隆抗体倡议阿昔替尼用以转移持续性黏膜黑色素瘤病变的Ib期分析的总猎食期和生物标志物统计分析。

时事：黑色素瘤/皮肤乳癌

创作者：北京大学病房郭军、盛锡楠博士等

内容可：10007

Safety and efficacy results of GC027: The first-in-human, universal CAR-T cell therapy for relapsed/refractory T-cell acute lymphoblastic leukemia (r/r T-ALL).Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Xinxin Wang, Shiqi Li, Lei Gao, Zhongtao Yuan, Kun Wu, Lin Liu, Le Luo, Yao Liu, Cheng Zhang, Jia Liu, Chunhui Yang, Yu Li, Jiaping He, Xun Ye, Zhimin Li, Xu Tan, Jianning Ge, Wei Cao, Sanbin Wang, Xi ZhangAbstract: 3013Poster: 77 GC027的安全持续性和结果：通用CAR-T细胞会首次体液试验放射治疗罹患/难治持续性T细胞会急持续性淋巴细胞会肺癌（r/r T-ALL）的安全持续性和。代表大会：研发里面的放射治疗技术-免疫放射治疗。创作者：王志欣等内容可：3013名片：77 Sintilimab in patients with advanced esophageal squamous cell carcinoma refractory to previous chemotherapy: A randomized, open-label phase II trial (ORIENT-2).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Jianming Xu, Yi Li, Qingxia Fan, Yongqian Shu, Zhijun Wu, Tongjian Cui, Kangsheng Gu, Min Tao, Xiuwen Wang, Chengxu Cui, Nong Xu, Juxiang Xiao, Quanli Gao, Yunpeng Liu, Tao Zhang, Hui Zhou, Yan Wang, Linxinyu Xu, Zhuo Ma, Yanqi WangAbstract: 4511Poster: 119 信迪利单抗在中后期食管楔形细胞会乳癌病变里面的运用于：一项随机的免费页面II期试验（ORIENT-2）。代表大会：肺肠道乳癌-肺食管乳癌、坏死乳癌和实乃道乳癌创作者：徐建明博士等内容可：4511名片：119 Eradication of medulloblastoma by NKG2D-specific CAR T-cells.Session: Central Nervous System TumorsAuthor(s): Hong-jiu Dai, Bin Sun, Dong Yang, Hui Xu, Jingjing Zhu, Jia Wei, Xudong ZhaoAbstract: 2522Poster: 13 NKG2D特异持续性CAR-T细胞会对髓母细胞会瘤的根除持续性放射治疗代表大会：神经系统创作者：代红久、孙斌、杨东、徐晖、朱晶晶、魏佳、赵旭东内容可：2522名片。13 Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Lin Shen, Jian Li, Yanhong Deng, Weijie Zhang, Aiping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, Did LiuAbstract: 3021Poster: 85 Envafolimab（KN035）在中后期错配修复缺陷病变里面的运用于代表大会：研发里面的放射治疗学-免疫放射治疗创作者：沈琳博士等内容可：3021名片。85 First-in-human clinical trial of the autologous CD7-CART for relapsed/refractory ACUTE lymphoblastic leukemia/lymphoma.Session: Developmental Therapeutics—ImmunotherapyAuthor(s): Mingzhi Zhang, Lin Yang, Xiaorui Fu, Lei Zhang, Huimin Meng, Ling Li, Xin Li, Xinhua Wang, Zhenchang Sun, Hui Yu, Zhaoming Li, Feifei Nan, Yu Chang, Zhiyuan Zhou, Jiaqin Yan, Jiwei Li, Min Wang, Fengtao You, Yu-Sheng Chen, Bozhen ZhangAbstract: 3026Poster: 90 自体CD7-CART放射治疗罹患/难治持续性ACUTE淋巴细胞会肺癌/白血病的首创体液外科试验代表大会: 研发持续性放射治疗学-免疫放射治疗创作者简介：张明志，杨林等内容可：3026名片: 90 A phase Ib study of simmitecan (LP) single-agent and in combination with 5-fluorouracil/leucovorin (5-FU/LV) or thalidomide (T) in patients with advanced solid tumor.Session: Developmental Therapeutics—Molecularly Targeted Agents and Tumor BiologyAuthor(s): Jifang Gong, Ting Deng, Jie Li, Ming Lu, Jian Li, Yi Ba, Qiuqiong Yu, Lin ShenAbstract: 3523Poster: 253 诺维奇替康（LP）单药和5-氟尿嘧啶/白藜芦醇（5-FU/LV）或沙利度胺（T）倡议运用于以中后期实体瘤病变的Ib期分析代表大会：发展持续性放射治疗学--大分子特异性抑制剂和生物学创作者：龚继芳，沈琳博士等内容可：3523名片：253 A phase II study of rh-endostatin combined with paclitaxel and nedaplatin in treating patients with recurrent or metastatic esophageal squamous cell carcinoma (ESCC).Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Zhiqiang Wang, Yu-Hong Li, De-Shen Wang, Fenghua Wang, Chao Ren, Qiong TanAbstract: 4522Poster: 130 Rh-endostatin倡议紫杉醇和nedaplatin放射治疗罹患持续性或转移持续性食管楔形细胞会乳癌（ESCC）病变的II期分析。代表大会：肺肠道乳癌-肺食管、坏死和实乃道乳癌的分析创作者：王志不强，杨玉红，王德申，王凤华，任超，谭琼 王志不强、杨玉红、王德深、王凤华、任超、谭琼内容可：4522名片：130 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.Session: Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and HepatobiliaryAuthor(s): Yan Song, Ning Li, Lan Mu, Shu Zhang, Qingxia Fan, Xinjun Liang, Xianli Yin, Zhixiang Zhuang, Yunpeng Liu, Jingdong Zhang, Xiaoge Kou, Haijun Zhong, Jing HuangAbstract: 4524Poster: 132 HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric adenocarcinoma: A phase II clinical trial.代表大会：肺肠道乳癌-肺食管乳癌、坏死乳癌和实乃管乳癌的二线放射治疗创作者：宋艳等内容可：4524名片：132 A urine exosomal circRNA classifier for detection of high-grade prostate cancer at initial biopsy: A multicenter, retrospective study.Session: Genitourinary Cancer—Prostate, Testicular, and PenileAuthor(s): Liaoyuan Li, Wen Tao, Yadi He, Tao He, Qing Li, Zhenquan Wu, Weiming Deng, Lingxiao ZhangAbstract: 5522Poster: 103 一种血液外体内环RNA分类器用以初始解剖时扫描高等级乳癌的血液外体内环RNA分类器：一项多外围的回顾持续性分析代表大会：外科生殖系统乳白血病--乳癌、睾丸乳癌和乳癌创作者简介：Liaoyuan Li等内容可：5522名片。103 Adjuvant chemotherapy after concurrent chemoradiation therapy for locally advanced cervical cancer.Session: Gynecologic CancerAuthor(s): Lingna Kou, Tao Zhang, Siyun Peng, Yifei Wang, Mingyang Yuan, Minmin LiAbstract: 6031Poster: 202 大面积中后期宫颈乳癌并发化疗后的特别设计化疗代表大会: 医学乳白血病创作者简介： 杨珉珉等内容可：6031名片：202 Association between calcitonin and efficacy of anlotinib in medullary thyroid carcinoma: An ysis based on the ALTER01031 trial.Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Pingzhang Tang, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6526Poster: 187 降钙素与安罗替尼放射治疗甲状腺髓持续性乳癌的相关持续性：基于ALTER01031试验的统计分析。会话：头颈部创作者：天津市病房实是博士内容可：6526名片。187 Influence of Eastern Cooperative Oncology Group performance status (ECOG PS), tumor size and age on patient outcomes after anlotinib treatment: A subgroup ysis based on ALTER01031 trial for medullary thyroid carcinoma (MTC).Session: Head and Neck CancerAuthor(s): Ming Gao, Yihebali Chi, Xiangqian Zheng, Dapeng Li, Pingzhang Tang, Zhengang Xu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan ChengAbstract: 6527Poster: 188 ECOG PS、大小和成年人对安洛替尼放射治疗后病变结局的不良影响: ALTER01031的亚组统计分析代表大会：头颈部创作者：天津市病房实是博士内容可：6527名片。188 Circulating tumor DNA (ctDNA) ysis predicts recurrence following surgery in patients with stage I-IIIA non-small-cell lung cancer (NSCLC): Results of GASTO1035 and GASTO1018.Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic CancersAuthor(s): Si-Yu Wang, Ning Li, Wei Ou, Chao Cheng, Peng-Peng Kuang, Hui-Qi WuAbstract: 9023Poster: 216 ctDNA统计分析预测I-IIIA期非小细胞会肺乳癌（NSCLC）病变术后罹患: GASTO1035和GASTO1018的结果代表大会：肺乳癌-非小细胞会大面积-区域持续性/小细胞会/小细胞会/其他胸科乳白血病创作者：Si-Yu Wang等内容可：9023名片：216 Exon-16-skipping ERBB2 (ERBB2ΔEx16) as a novel resistance mechanism against EGFR tyrosine kinase inhibitors in non-small cell lung cancer (NSCLC).Session: Lung Cancer—Non-Small Cell MetastaticAuthor(s): Xin Zhao, Linling Jin, Man Yu, Qiuxiang Ou, Hua Bao, Xue Wu, Yang Shao, Min FanAbstract: 9528Poster: 294 ERBB2ΔEx16作为非小细胞会肺乳癌（NSCLC）里面EGFR乙酰丝氨酸抑制剂的新型耐药性选择性代表大会:肺乳癌-非小细胞会转移持续性肺乳癌创作者简介：赵昕，金玲玲，满宇，欧娘子，华宝，薛武，杨少，范敏 赵昕、金玲玲、满宇、欧娘子、华宝、薛武、杨绍、范敏内容可：9528名片：294 Surrogate endpoints for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials of advanced melanoma.Session: Melanoma/Skin CancersAuthor(s): Run-Cong Nie, Shu-Qiang Yuan, Yuanfang Li, Yingbo Chen, Zhiwei ZhouAbstract: 10030Poster: 379 PD-1/PD-L1试验里面中后期黑色素瘤总猎食的替代起始站代表大会：黑色素瘤/皮肤乳癌创作者：聂润聪，袁书不强，杨元芳，陈英波，周志伟 聂润聪、袁书不强、杨元芳、陈英波、周志伟内容可：10030名片：379 A phase II study of anlotinib in treating patients with relapsed or metastatic primary malignant bone tumor.Session: SarcomaAuthor(s): Lina Tang, Xiaohui Niu, Zhen Wang, Qiqing Cai, Chongqi Tu, Zhengfu Fan, Yang YaoAbstract: 11525Poster: 413 安罗替尼放射治疗罹患或转移持续性原发持续性恶持续性肩胛骨病变的II期分析代表大会： 遗传性创作者：唐丽娜，牛晓辉，王震，蔡启清，涂崇奇，范正福，杨瑶 唐丽娜、牛晓辉、王振、蔡启庆、涂崇奇、范正福、杨瑶内容可：11525名片。413 Preliminary evaluate the safety and efficacy of anlotinib in advanced sarcoma patients in multi-line therapy.Session: SarcomaAuthor(s): Yao Weitao, Jiaqiang Wang, Peng Zhang, Xin Wang, Xinhui Du, Zhichao Tian, Xiaoying NiuAbstract: 11526Poster: 414 初步评价安罗替尼在中后期遗传性病变多线放射治疗里面的安全持续性和。代表大会：遗传性创作者：姚伟涛，王家不强，张春，王志，杜新辉，田志浩，牛晓颖 姚伟涛、王家不强、张春、王鑫、杜鑫辉、田志超、牛晓英内容可：11526名片：414